Darlene Staines

Goodwin

Contact
View Bio
RSS

Latest Posts › Samsung Bioepis

Share:

Harrow Enters Agreement to Commercialize Samsung Bioepis’s Ophthalmology Biosimilars Following Biogen’s Exit

On July 17, 2025, Harrow, Inc. (“Harrow”), announced an agreement with Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) to acquire the U.S. commercial rights to two of Samsung Bioepis’s biosimilars, BYOOVIZ® (ranibizumab-nuna)...more

7/30/2025  /  Biosimilars , Biotechnology , Contract Terms , FDA Approval , Intellectual Property Protection , Pharmaceutical Industry , Pharmaceutical Patents , Prescription Drugs , Samsung Bioepis

Teva and Samsung Bioepis Announce U.S. Launch of EPYSQLI® (eculizumab-aagh), a SOLIRIS® Biosimilar

On April 7, 2025, Teva Pharmaceuticals and Samsung Bioepis Co., Ltd. announced the U.S. launch of EPYSQLI® (eculizumab-aagh), a biosimilar referencing Alexion Pharmaceuticals’ SOLIRIS®....more

4/10/2025  /  Biosimilars , Drug Pricing , FDA Approval , Partnerships , Patents , Pharmaceutical Industry , Pharmaceutical Patents , Prescription Drugs , Samsung Bioepis , Teva Pharmaceuticals
2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide